|Bid||46.00 x 800|
|Ask||0.00 x 3000|
|Day's Range||50.40 - 51.82|
|52 Week Range||44.36 - 88.68|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||22.51|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||1.48 (2.91%)|
|1y Target Est||74.25|
Nu Skin (NUS) focuses on capturing greater market share through sales leaders. However, the company is battling currency headwinds.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
PROVO, Utah , May 7, 2019 /PRNewswire/ -- Premier beauty and wellness company Nu Skin has been ranked the world's number one at-home beauty device system brand for 2017 and 2018 by Euromonitor International ...
NU Skin Enterprises Inc NYSE:NUSView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for NUS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting NUS. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.73 billion over the last one-month into ETFs that hold NUS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Services sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Herbalife (NYSE:HLF) is no stranger to headlines. We all remember the wild moves on the verbal jabs between two titans of investing. Bill Ackman openly shorted the stock and Carl Icahn fiercely defended it. The fight went on for months but has since faded away.Source: Aybek Erkinov via FlickrToday, HLF stock is moving on a different kind of headline. Last night they reported earnings and investors hated the results. They missed both on the top and bottom lines. Also they made no headway against last year's numbers so there was little to celebrate.These day traders are quick to sell stock on even good reports, so they will sure sell the bad one. To make matters worse, management guided full-year numbers that are lower than anticipated. That alone is reason enough to crater the Herbalife stock. Frankly I am surprised that the drop isn't bigger than this 4% dip on headline. Perhaps it is because the stock came into the earnings down 10% already when the S&P 500 is up 16% year to date.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What's Next for HLF StockSo is this a good time to catch the falling knife? Unfortunately there isn't one definitive answer because it all depends on the investor time frame and thesis.Fundamentally, HLF is not cheap. It sells at a 26 trailing price-to-earnings ratio, which is almost twice that of Apple (NASDAQ:AAPL), for example. This could be symptomatic of the industry because it is in line with Nu Skin (NYSE:NUS) valuation. * 10 Cheap Stocks to Buy in May, But Don't Go Away Nevertheless, if there is trouble on Wall Street, I'd bet that there is much more froth to come out of the HLF stock. This is not a knock against the company or its prospects. This is more to do with assessing the downside risk should the selling persist.This week, we have seen more negative rhetoric calling for marketwide tops. Although I disagree with them, I have to respect the possibility that they are correct. This is proper risk management -- regardless of my own opinion, I have to consider all scenarios in play.Technically, HLF stock has a ton of trouble looming just below the surface. But luckily, so far the bulls have succeeded in defending the $50 level. In fact while the S&P 500 fell into its lows in December, Herbalife climbed higher from its bottom two months earlier. That is a sign of solid support.The bad news is, that makes the line very important to hold. If for any reason the bulls lose it, then they trigger a bearish pattern to target $47.50 first then $42 or lower. This again is not a forecast, but it is one of the possible scenarios at hand.Last night's earnings report did not hold much good news, so it is hard to gauge if the weakness in their business will persist. Hopefully management guided lower to a number that they can actually beat, so they can over-deliver in three months.The macroeconomic environment still favors the bullish thesis, but there are a lot of geopolitical threats that loom -- mainly from the tariff wars. Sentiment, while much improved from last year, is still delicate. The bulls have one foot out the door at all times while we are still close to an all-time high.The currency markets have been wild of late due to manipulation from the global central banks. This no doubt played a role in hurting Herbalife's business. Regardless, the sales line needs to show growth for the company to continue to command its premium on Wall Street. Otherwise investors will reconsider their valuations for it.This is a bottom that should hold even after the bad news of the quarter. So if I am already long I can hold out a few more ticks with proper stop losses. But if I want to start a new position now, it should be a fundamental one, meaning I'd be ready to hold it for the long term in case the price continues lower.Otherwise, I'd classify it as a tactical trade and I'd need to be nimble with my stop orders. Else I'd risk turning a trade into an investment.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best Stocks to Buy for May * 7 Stocks Worth Buying When They're Down * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post There Is Good News in Herbalife's Post-Earnings Action appeared first on InvestorPlace.
Earnings helped some stocks outperform as the latest Federal Reserve decision kept markets in check.
Nu Skin stock exploded after the firm handily beat earnings estimates. But Estee Lauder stock reversed lower after it bested analyst expectations.
The performance can be attributed to Nu Skin's (NUS) technology and business expansion initiatives as well as customer acquisition and retention program.
On a per-share basis, the Provo, Utah-based company said it had net income of 77 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
PROVO, Utah , April 30, 2019 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced first-quarter 2019 results. Executive Summary Q1 2019 vs. Prior-Year Quarter Revenue: $623.6 million, ...
PROVO, Utah , April 30, 2019 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.37 per share, which will be paid on ...
NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Nu Skin Enterprises, Inc. (NYSE: NUS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 30, 2019 at 5:00 PM ...
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
PROVO, Utah, April 25, 2019 /PRNewswire/ -- Nu Skin was recognized as one of the best places to work by Direct Selling News for the fourth consecutive year at the publication's annual awards dinner. In addition, Nu Skin was ranked #7 on the DSN Global 100 list of the top revenue-generating direct selling companies. To identify the best places to work, Direct Selling News surveyed thousands of employees throughout the industry, asking questions designed to quantify discretionary effort, intent to stay and advocacy for company as well as measure workplace culture and employee engagement.
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nu Skin's (NUS) is likely to benefit from effective marketing programs, gains from social media and a solid sales leaders' network. These factors are set to drive customer count in Q1.
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results between individual stocks. At this point some shareholders may be questioning their investment in Nu Skin E...
In a trading world where investors seek the latest technology or the newest trend, personal products stocks tend to receive less attention. As an older industry which mostly produces commoditized products, investment interest in this sector tends to revolve around preserving existing wealth or generating dividend income. * 7 Stocks to Buy for Spring Season Growth Despite the perception, these firms may receive more attention as they innovate on product development or marketing. Also, a growing presence in emerging markets has also bolstered these consumer staples stocks. Although many personal products stocks could bring opportunity, these three appear especially well-positioned to profit investors:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Herbalife (HLF)Source: Aybek Erkinov via FlickrOne can argue that Herbalife (NYSE:HLF) has become better-known for hedge fund interest than what the firm produces. However, with Carl Icahn finally winning on his long bet against short-seller Bill Ackman, traders can evaluate HLF stock on sales and profit growth.The Cayman Islands-based nutrition company makes products for nutrition, energy, sports and fitness. However, its weight management segment drives more than 50% of its revenue. Though weight management encompasses multiple products, the division centers on its original product, protein shake. This Formula 1 shake is a soy-based product marketed as a "meal replacement." The company sells its product directly to the public via multi-level marketing.Unlike most personal products stocks, HLF acts as more of a growth equity. While it does not pay a dividend, it has begun to post improving growth numbers. After stagnating in the middle of the decade, revenues again started to increase in 2018. Revenue growth seems to have returned as Wall Street predicts a 6.1% increase for this year and 6.6% growth in 2020.As a result, profit increases have returned to double-digit levels, with earnings rising by 10.1% this year. This takes the forward P/E ratio to just under 14.4.HLF stock can rise, the question is how much? Herbalife currently trades at almost $53 per share. The one point of concern is it appears to have become stuck in a range. Since last August, it has twice pulled back from the low $60s per share level. I think the improving profit outlook can at least take it back to that level. However, it will need to break out of this range to sustain a longer-term upward trend. Nu Skin Enterprises (NUS)Nu Skin Enterprises (NYSE:NUS) is a multilevel marketing company who produces and sells both dietary supplements and personal care products. They market under the Nu Skin and Pharmanex brand names.The Provo, Utah-based firm operates in about 50 markets worldwide. According to the company's 10-K, they derive about 88% of their revenue from outside the U.S. Its largest market, mainland China, accounts for around 33% of that revenue.Like most personal products stocks, NUS stock pays a dividend. The current annual payout of $1.48 per share has increased every year since 2001. For new shareholders, it also yields around 2.9%, well above S&P 500 averages.A falling stock price may explain the relatively high yield. Over the last six months, the equity has lost over 40% of its value. This decline stems from its significant presence in China and investigations. Chinese authorities allege firms such as Nu Skin engaged in the unlawful promotion of health and wellness products. In early January, China instituted a 100-day ban on business meetings.The uncertainty surrounding this probe has hammered NUS stock. Consequently, investors may have a buying opportunity. NUS stock now trades at a forward P/E ratio of 11.6. Equities forecasted to increase profits by an average of 11.35% per year over the next five years rarely trade at such a low multiple. * 10 S&P 500 Stocks to Weather the Earnings Storm The tenuous situation in China adds to the risk of NUS stock. For this reason, it might make sense to wait or to buy only for the dividend. However, I think once the current crackdown ends, investors will hold a low-priced, high-growth stock with a generous payout. Unilever (UL, UN)Investors often confuse the stocks of London-based Unilever PLC (NYSE:UL) and Unilever N.V. (NYSE:UN) based in the Netherlands. Despite the legal separation, both are Unilever. It maintains this dual headquarters arrangement and two tickers for a variety of reasons. Still, while UN faces higher dividend taxes, UL and UN remain almost identical for purposes of U.S. traders.Unilever owns a wide variety of consumer brands including Ben & Jerry's Ice Cream, Lipton Tea, Dove soap, and Axe skin products. In 2018, it derived about 60% of its revenue from personal products. The remainder came from packaged food-type products. It has undergone cost-cutting initiatives over the last few years and has aggressively moved into emerging markets.Over the long-term, UL and UN stock have generally risen, though it has stagnated over the last year. As of this writing, UN trades at about $57.50 per share, near its 52-week high. Still, both tickers support a forward P/E of about 20. Also, analysts expect an average 9.3% per year increase in profits over the next five years.For this reason, most of the benefit of owning UL and UN stock comes from the dividend. Since the company pays in pounds and euro, payouts may fluctuate. However, the stocks currently yield about 3.05%. Dividends also rise annually, at least when measured in the currency of their respective countries.Unilever may trade at a somewhat higher multiple compared to other personal products stocks. However, with its growing presence in emerging markets, both UN and UL stock can become a profitable growth and income play.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile Compare Brokers The post 3 Personal Products Stocks to Revitalize Your Portfolio appeared first on InvestorPlace.
Nu Skin (NUS) gains from an expanding customer base and prudent product launches. However, persistent decline in gross margin is a concern.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Nu Skin Enterprises, Inc. (NYSE:NUS) is a stock with outstanding fundamental characteristics. When we build an inves...